Secondary hematologic malignancies associated with temozolomide (TMZ) in patients with glioma.

被引：1
|
作者：
Momota, H.
Narita, Y.
Miyakita, Y.
Shibui, S.
机构：
[1] Nagoya Univ, Nagoya, Aichi 4648601, Japan
[2] Natl Canc Ctr, Tokyo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.2046
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2046
引用
收藏
页数：1
相关论文
共 50 条
  • [21] RADIOTHERAPY WITH CONCOMITANT AND ADYUVANT TEMOZOLOMIDE WITH OR WITHOUT CARMUSTUNE WAFERS IN HIGH GRADE GLIOMA.
    Quiros, J.
    RADIOTHERAPY AND ONCOLOGY, 2010, 96 : S269 - S269
  • [22] Temozolomide (TMZ) with O6-benzylguanine (BG) for TMZ-resistant malignant glioma: A phase 2 trial
    Desjardins, A
    Quinn, J
    Reardon, D
    Rich, J
    Sathornsumetee, S
    Vredenburgh, J
    Walker, A
    Tourt-Uhlig, S
    Bigner, D
    Friedman, H
    NEURO-ONCOLOGY, 2005, 7 (03) : 401 - 401
  • [23] TREATMENT OUTCOMES FOR PATIENTS WITH ANAPLASTIC ASTROCYTOMAS TREATED WITH RADIATION AND TEMOZOLOMIDE (TMZ) AND MAINTENANCE TMZ
    Sheth, Ravi
    Grimm, Sean
    Helenowski, Irene
    Rademaker, Alfred
    Raizer, Jeffrey
    NEURO-ONCOLOGY, 2011, 13 : 59 - 59
  • [24] Fatal Pneumonia Associated with Temozolomide Therapy in Patients with Malignant Glioma
    Hayashi, Hiroki
    Saito, Yoshinobu
    Kokuho, Nariaki
    Morimoto, Taisuke
    Kobayashi, Kenichi
    Tanaka, Toru
    Abe, Shinji
    Fujita, Kazue
    Azuma, Arata
    Gemma, Akihiko
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2012, 42 (07) : 632 - 636
  • [25] Temozolomide (TMZ) as salvage therapy for patients with recurrent gliomas who previously responded to TMZ
    Franceschi, E
    Omuro, AMP
    Nolan, C
    Lassman, A
    Demopoulos, A
    Abrey, IE
    NEURO-ONCOLOGY, 2004, 6 (04) : 374 - 375
  • [26] SECONDARY HEMATOLOGIC MALIGNANCIES IN PREVIOUSLY-TREATED PATIENTS WITH SOLID TUMOR
    Choi, Y. H.
    Kang, H. J.
    Na, I.
    Lee, H. R.
    Lee, J. K.
    Chang, Y. H.
    Yang, S.
    HAEMATOLOGICA, 2012, 97 : 584 - 585
  • [27] THE TEMOZOLOMIDE RESCUE STUDY: A PHASE II TRIAL OF CONTINUOUS (28/28) DOSE-INTENSE TEMOZOLOMIDE (TMZ) AFTER PROGRESSION ON CONVENTIONAL 5/28 DAY TMZ IN PATIENTS WITH RECURRENT MALIGNANT GLIOMA
    Perry, J.
    Mason, W.
    Belanger, K.
    Kavan, P.
    Fulton, D.
    Easaw, J.
    Kirby, S.
    Macdonald, D.
    Shields, C.
    Pouliot, J. F.
    NEURO-ONCOLOGY, 2008, 10 (06) : 1063 - 1063
  • [28] The temozolomide RESCUE study: A phase II trial of continuous (28/28) dose-intense temozolomide (TMZ) after progression on conventional 5/28 day TMZ in patients with recurrent malignant glioma
    Perry, J. R.
    Mason, W. P.
    Belanger, K.
    Kavan, P.
    Fulton, D.
    Easaw, J.
    Kirby, S.
    Macdonald, D.
    Shields, C.
    Pouliot, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [29] The landscape of EGFR mutation in Chinese patients with glioma.
    Zhang, Hui
    Tao, Rongjie
    Zhu, Xiaofeng
    Luo, Ningning
    Qi, Yingxue
    Li, Mengmeng
    Sun, Tingting
    Qi, Chuang
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [30] FACTORS ASSOCIATED WITH MORTALITY IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES AND SEPTIC SHOCK
    Manjappachar, Nirmala
    Cuenca, John
    Ramirez, Claudia
    Martin, Peyton
    Gutierrez, Cristina
    Reddy, Dereddi Raja
    Botdorf, Joshua
    Rathi, Nisha
    Price, Kristen
    Nates, Joseph
    CRITICAL CARE MEDICINE, 2022, 50 (01) : 306 - 306
12345